Nimbus Therapeutics of Cambridge, MA, has hired Adrian Ray as senior vice president of discovery biology as it advances its immunology and oncology pipeline. Ray comes from Gilead Sciences (NASDAQ: [[ticker:GILD]]), where he spent 15 years, most recently as senior director of clinical research.
Nimbus and Foster City, CA-based Gilead are familiar with each other. In 2016, Gilead paid $400 million upfront to acquire a potential treatment for nonalcoholic steatohepatitis, an increasingly common liver disease, from privately held Nimbus. The startup has used early investment from chemistry-simulation software maker Schrödinger, Bill Gates, and others to pursue a computationally intensive drug discovery strategy. Nimbus recently announced a new round of funding from its previous backers.
